Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study.
Mario IannacconeFabrizio D AscenzoOvidio De FilippoMarco GagliardiDanielle A SouthernSergio Raposeiras-RoubínEmad Abu-AssiJose Paulo Simao HenriquesJorge SaucedoJosé Ramón González-JuanateyStephen B WiltonWouter J KikkertIván Nuñez-GilAlbert Ariza-SoleXiantao SongDimitrios AlexopoulosChristoph LiebetrauTetsuma KawajiZenon HuczekShao-Ping NieToshiharu FujiiLuis CorreiaMasa-Aki KawashiriJosé María García-AcuñaEmilio AlfonsoBelén TerolAlberto GarayDongfeng ZhangYalei ChenIoanna XanthopoulouNeriman OsmanHelge MöllmannHiroki ShiomiMichal KowaraKrzysztof FilipiakXiao WangYan YanJing-Yao FanYuji IkariTakuya NakahashiKenji SakataMasakazu YamagishiClaudio MorettiFiorenzo GaitaOliver KalpakSasko KedevPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2017)
In patients with ACS and malignancy, OMT reduces the risk of adverse events at 1 year; in particular, ACEIs/ARBs and statins were the most protective drugs. (Clinical trials identifier: NCT02466854).
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- clinical trial
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery bypass grafting
- healthcare
- randomized controlled trial
- heart failure
- type diabetes
- phase ii
- drug induced
- open label